mammary Paget disease

Summary

mammary Paget disease (MONDO:0002648) is a disease and 1 clinical trial. Top therapeutic interventions include doconexent. A subtype of breast adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	mammary Paget disease
Mondo ID	MONDO:0002648
MeSH	D010144
DOID	DOID:3443
NCIT	C47857
UMLS	C0030185
MedGen	18263
Anatomy (UBERON)	UBERON:0000310
Is cancer (heuristic)	no

Also known as: breast Paget disease · mammary Paget disease · mammary Paget’s disease · Paget disease of the breast · Paget’s disease of breast · Paget’s disease of the breast

Disease family

This is a subtype of breast adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › integumentary system cancer › breast adenocarcinoma › mammary Paget disease

Related subtypes (12): breast lobular carcinoma, signet ring cell breast carcinoma, breast mucinous cystadenocarcinoma, mucoepidermoid breast carcinoma, adenoid cystic breast carcinoma, sebaceous breast carcinoma, oncocytic breast carcinoma, breast malignant eccrine spiradenoma, breast ductal adenocarcinoma, lobular breast carcinoma in situ, mixed lobular and ductal breast carcinoma, inflammatory breast carcinoma

Subtypes (1): Paget disease of the nipple

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Doconexent.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01849250	PHASE2	COMPLETED	Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DOCONEXENT	3	1
CHEMBL4439413	0	1